SINGAPORE - Cynosure Lutronic, a global leader in energy-based medical aesthetic devices, announced today that Clarity II, its dual-wavelength long-pulse laser platform, has received regulatory approval in China and Japan. This marks a significant expansion of the company's clinically approved laser portfolio across two of Asia's most highly regulated aesthetic markets. 

"The approval enables the introduction of a single, integrated dual wavelength laser platform designed to support multiple treatment indications and diverse patient profiles and is also reflective of Cynosure Lutronic's growing strength across the Asia Pacific region" said Nadav Tomer, CEO of Cynosure Lutronic.

China: Regulatory Approval

In China, Clarity II (marketed as CLARITY II ICD) has received regulatory approval for use in medical institutions as of 12th February 2026.  

• Product Name: Clarity II ICD
• Approved Indications:
• 755nm laser – approved to reduce wrinkles on the cheeks
• 1064nm laser – approved to reduce unwanted body hair

The approval authorizes the use of a single integrated platform across multiple treatment applications within regulated clinical settings of China.

Japan: Regulatory Approval

In Japan, Clarity II has received regulatory clearance as of 9th January 2026 for use in medical aesthetic practices.

• Product Name: Clarity II
• Approved Indication:
• Alexandrite 755nm / Nd:YAG 1064nm approved for Long-term hair reduction

The clearance confirms compliance with Japan's stringent medical device regulatory requirements for laser-based aesthetic treatments. 

Clinical and Operational Context

In both China and Japan, medical aesthetic practices are operating under increasingly rigorous regulatory and clinical expectations, with heightened emphasis on treatment precision, indication-specific use, and safety.

The regulatory approvals of Clarity II reflect growing demand for laser platforms that consolidate multiple clinically validated applications within a single system, while maintaining strict control over energy delivery and treatment parameters. In China, approval across both hair removal and wrinkle treatment applications enables practitioners to address multiple patient needs with one versatile platform. In Japan, clearance of the latest-generation system reinforces confidence in technological refinement and output consistency within a highly regulated clinical environment.

Together, these approvals position Clarity II as a platform aligned with the evolving standards of advanced aesthetic practice in Asia compliance, and clinical versatility are increasingly critical.